



## **Zedira licenses ZED-101 for celiac disease therapy to Dr. Falk Pharma in Europe**

**Darmstadt, November 25<sup>th</sup> 2011**

Zedira GmbH today announced that it has licensed exclusive rights to develop and market ZED-101 in Europe to Dr. Falk Pharma GmbH, Germany. ZED-101 is a new chemical entity blocking specifically tissue transglutaminase. Tissue transglutaminase is the key player in pathogenesis of celiac disease.

Under the terms of the agreement, Dr. Falk Pharma GmbH takes over preclinical and clinical development as well as marketing of the drug.

Zedira receives an upfront payment and may receive further milestone payments as well as royalties.

**Celiac Disease** is the most common chronic inflammation of the small intestine. The autoimmune disease is caused by alimentary gluten in genetically susceptible individuals.

### **About Zedira:**

The Darmstadt-based biotech company focuses on celiac disease and consequently also on the transglutaminase family of enzymes. The Company develops, produces and markets products for research and development as well as for diagnostics. Based on its proprietary family of low-molecular transglutaminase blockers, Zedira is establishing an active ingredient pipeline covering the primary indication of celiac disease. As an area of secondary indication the Company is working on new approaches to thrombosis prophylaxis. Zedira is a portfolio company of the German High-Tech Gründerfonds.

### **About Dr. Falk Pharma:**

Dr. Falk Pharma GmbH specializes in the development and marketing of pharmaceuticals used in hepatology and gastroenterology. Falk is one of the leading European companies in the field marketing its products by means of subsidiaries in selected countries and a network of sales partners. Furthermore, the Falk Foundation, an independent organization associated with Dr. Falk Pharma, is well-known for its international symposia, forums and educational literature supporting medical doctors, patients and their families.

Zedira GmbH  
Dr. Ralf Pasternack  
Dr. Martin Hils  
Roesslerstr. 83  
64295 Darmstadt  
Telefon: +49 6151 325100  
Fax: +49 6151 325119

Web: [www.zedira.com](http://www.zedira.com)  
E-Mail: [contact@zedira.com](mailto:contact@zedira.com)

© 2011, [Zedira GmbH](#)